Today's Reuters Health News Headlines - Yahoo! News:
|
|
Olympus ex-CEO to meet Japan ruling party
Sun,11 Dec 2011 10:27 PM PST
Reuters -  TOKYO (Reuters) - Olympus Corp's ousted CEO, Michael Woodford, will on Thursday meet a panel of lawmakers from Japan's ruling Democratic Party looking at ways to tighten corporate governance in the wake of the accounting scandal at the endoscope maker, a source familiar with the plan told Reuters. Woodford may also meet lawmakers from the opposition Liberal Democratic Party of Japan, the source said on Monday on condition he wasn't identified. ...
Full Story | Top |
Olympus ex-CEO to meet Japan ruling party on corporate
Sun,11 Dec 2011 10:25 PM PST
Reuters - TOKYO (Reuters) - Olympus Corp's ousted CEO, Michael Woodford, will on Thursday meet a panel of lawmakers from Japan's ruling Democratic Party looking at ways to tighten corporate governance in the wake of the accounting scandal at the endoscope maker, a source familiar with the plan told Reuters. Woodford may also meet lawmakers from the opposition Liberal Democratic Party of Japan, the source said on Monday on condition he wasn't identified. ... Full Story | Top |
Memory issues after cancer may not be due to chemo
Sun,11 Dec 2011 10:15 PM PST
Reuters - NEW YORK (Reuters Health) - Women treated for breast cancer with radiation with or without chemotherapy had more thinking and memory problems a few years after their treatment ended than women who'd never had cancer, in a new study. Research has suggested some women experience mental haziness, dubbed "chemo brain," during and soon after chemotherapy treatment. And one recent study found evidence of changes in the activity of certain brain regions in women who'd undergone chemotherapy (see Reuters Health story of November 15, 2011). ... Full Story | Top |
Olympus preparing to file earnings by Wednesday
Sun,11 Dec 2011 08:34 PM PST
Reuters -  TOKYO (Reuters) - Olympus said it was preparing to file its July-September earnings by Wednesday, a necessary step for the disgraced 92-year-old firm to remain listed. The Japanese maker of cameras and endoscopes also said it would hold a briefing on Thursday to explain the results, after admitting to a $1.7 billion scheme to hide investment losses stretching back more than a decade. The scandal has put the company's future at risk. Even if Olympus meets the earnings deadline, the Tokyo Stock Exchange can still decide to delist Olympus depending on the scale of its past misreportings. ...
Full Story | Top |
U.S.-listed firms told to reveal Syria, Iran links: FT
Sun,11 Dec 2011 07:43 PM PST
Reuters -  NEW YORK (Reuters) - At least a dozen U.S.-listed companies have been told by the U.S. Securities and Exchange Commission to disclose business activity in and with Syria, Iran and others deemed "state sponsors" of terror by the state department, the Financial Times said on Sunday. The inquiries are part of SEC reviews of companies' investment risks to security holders. Sony Corp, Caterpillar Inc, American Express, Aecom Technology, Iridex and Veolia Environnement are among the companies that received letters from the SEC's corporate finance division, the report said. ...
Full Story | Top |
Ariad leukemia drug helps 47 percent of patient: study
Sun,11 Dec 2011 04:31 PM PST
Reuters - SAN DIEGO (Reuters) - Early results from a pivotal trial of Ariad Pharmaceuticals Inc's experimental leukemia drug ponatinib show it is effective in nearly half of patients who had stopped responding to currently available drugs. An interim look at the study, presented here at a meeting of the American Society of Hematology, shows that 47 percent of chronic myeloid leukemia (CML) patients with chronic-phase disease had a major response to ponatinib, meaning that at least two-thirds of their bone marrow was normal. ... Full Story | Top |
Analysis: U.S. focus on birth control may raise new concerns
Sun,11 Dec 2011 11:05 AM PST
Reuters -  WASHINGTON (Reuters) - A ruling last week on the morning-after pill, as well as government recommendations on new forms of birth control, could have long-lasting effects on women's perceptions of its safety, health experts say. Last Wednesday, the health secretary for the first time overruled government scientists, refusing to make the morning--after pill available to users of all ages without a prescription. ...
Full Story | Top |
Bayer CEO eyes falling margins in drugs, plastics
Sun,11 Dec 2011 11:01 AM PST
Reuters - FRANKFURT (Reuters) - Bayer expects to see falling profit margins in drugs and plastics as the euro debt crisis sends tremors through economy, chief executive Marijn Dekkers told a German newspaper. "There is an increasing trend towards cost-cutting on medicines, so the debt crisis is pressuring our margins," Dekkers told Tagesspiegel newspaper in a interview released ahead of publication on Monday. "Besides price pressure in HealthCare, demand is weakening for our plastics," he said. ... Full Story | Top |
Pharmacyclics' blood cancer drug responses rise
Sun,11 Dec 2011 08:04 AM PST
Reuters - SAN DIEGO (Reuters) - Interim results from an early stage trial of Pharmacyclics Inc's experimental blood cancer drug show the number of leukemia patients responding to the medicine has increased over time. At 10 months follow-up, 70 percent of patients treated with the lower dose of the drug, known as PCI-32756, had a significant improvement in their condition. That is up from the 48 percent response rate reported by trial investigators after six months of follow-up. ... Full Story | Top |
Gingrich fights off rivals in Iowa debate
Sat,10 Dec 2011 09:05 PM PST
Reuters -  DES MOINES, Iowa (Reuters) - Surging frontrunner Newt Gingrich fought off heavy attacks in a presidential debate in Iowa on Saturday from Republican rivals who portrayed him as a Washington insider and questioned his judgment. Gingrich, described by some critics as rash and petulant, kept his cool as his Republican rivals criticized him for making up to $1.6 million from housing giant Freddie Mac, for saying Palestinians were an "invented" people and for his troubled marital past. ...
Full Story | Top |
Romney's $10,000 bet falls flat in Iowa debate
Sat,10 Dec 2011 07:58 PM PST
Reuters -  DES MOINES (Reuters) - Republican presidential candidate Mitt Romney put his money where his mouth was on Saturday in a quip at a presidential debate that may have backfired. Romney, a multi-millionaire and a frontrunner for the Republican nomination, offered a $10,000 bet to opponent Texas Gov. Rick Perry in an argument over what Romney wrote about healthcare in his book "No Apologies." Former Massachusetts governor Romney tried to bet that he had not supported implementing an individual healthcare mandate, mistrusted by conservatives. "Rick, I'll tell you what: 10,000 bucks?," Romney said. ...
Full Story | Top |
Gene therapy proves effective for hemophilia B
Sat,10 Dec 2011 07:11 PM PST
Reuters - SAN DIEGO (Reuters) - A single treatment with gene therapy, an experimental technique for fixing faulty genes, has been shown to boost output of a vital blood clotting factor, possibly offering a long-term solution for people with hemophilia B. Researchers said the same technology was also being studied as a treatment for hemophilia A, the far more common type of the inherited bleeding disorder. "It is a technique for potentially permanently curing patients," said Dr. ... Full Story | Top |
Gene therapy proves effective for hemophilia B
Sat,10 Dec 2011 12:42 PM PST
Reuters - SAN DIEGO (Reuters) - A single treatment with gene therapy, an experimental technique for fixing faulty genes, has been shown for the first time to boost output of a vital blood clotting factor, possibly offering a long-term solution for people with hemophilia B. Researchers said the same technology was also being studied as a treatment for hemophilia A, the far more common type of the inherited bleeding disorder. "It is a technique for potentially permanently curing patients," said Dr. ... Full Story | Top |
Gingrich vs Romney rivalry in Iowa debate spotlight
Sat,10 Dec 2011 12:25 PM PST
Reuters -  DES MOINES, Iowa (Reuters) - The budding rivalry between surging Newt Gingrich and former frontrunner Mitt Romney will take center stage on Saturday in the first of two Republican presidential debates in Iowa over the next five days. Gingrich, Romney and four other White House contenders will make their case to voters in a race that polls show is still up for grabs less than a month before Iowa kicks off the state-by-state Republican nominating contest. The debate will be broadcast nationally on ABC at 9 p.m. EST from Drake University in Des Moines. ...
Full Story | Top |
Leukemia drug pulled from U.S. sparks new interest
Sat,10 Dec 2011 11:56 AM PST
Reuters - SAN DIEGO (Reuters) - A new study of leukemia drug Mylotarg, pulled from the U.S. market last year due to safety concerns, found it to be effective when used at low doses in older adults but questions about toxicity remain. Pfizer Inc voluntarily halted U.S. sales of Mylotarg, also known as gemtuzumab, after a study showed that adding it to chemotherapy did not extend survival for patients with previously untreated acute myeloid leukemia (AML), an aggressive bone marrow cancer. That trial also showed more deaths in the first couple of months of treatment. The fatality rate was 5. ... Full Story | Top |
| |
|
No comments:
Post a Comment